Quest Highlights Diagnostics Pipeline As Key Component Of Celera Purchase
This article was originally published in The Gray Sheet
Executive Summary
Quest Diagnostics will expand its molecular diagnostic product offerings and gain a substantial biomarker R&D pipeline while boosting its cardiovascular testing services business through the purchase of Celera for $344 million in cash.
You may also be interested in...
Medical Device and In Vitro Diagnostics/Research Deals Statistics Quarterly, Q1 2011
For the first three months of 2011, medical device companies raised $733 million, with venture rounds bringing in $494 million. Two-thirds of the $3.9 billion in M&A activity came from Terumo's monstrous $2.6 billion cash takeover of US blood processing equipment maker CaridianBCT Holding. Buoyed by Opko Health's $105 million follow-on, the FOPO category represented almost half of the first quarter's in vitro diagnostics/research $370 million total. The stand-out IVD acquisition was Danaher's $6.8 billion takeover of publicly traded Beckman Coulter.
Medical Device and In Vitro Diagnostics/Research Deals Statistics Quarterly, Q1 2011
For the first three months of 2011, medical device companies raised $733 million, with venture rounds bringing in $494 million. Two-thirds of the $3.9 billion in M&A activity came from Terumo's monstrous $2.6 billion cash takeover of US blood processing equipment maker CaridianBCT Holding. Buoyed by Opko Health's $105 million follow-on, the FOPO category represented almost half of the first quarter's in vitro diagnostics/research $370 million total. The stand-out IVD acquisition was Danaher's $6.8 billion takeover of publicly traded Beckman Coulter.
News In Brief
J&J/Synthes merger talks ongoing